SynthesisJournal of medical imaging and radiation oncology2026
Dynamic SPECT Assessment of Hepatic Function in Patients With Liver Disease: A Systematic Review and Meta-Analysis.
Synthesis in Journal of medical imaging and radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDynamic Single Photon Emission Computed Tomography (dynSPECT) is an advanced functional imaging modality that enables estimation of temporal changes in radiopharmaceutical distribution and physiological function. While dynSPECT has been employed in several clinical applications, it has not been widely applied to liver imaging. This review aims to investigate the role and effectiveness of dynSPECT in assessing hepatic function.
methodsFollowing PRISMA guidelines, literature searches were conducted in MEDLINE, PubMed, Scopus, Embase, IEEE, and Web of Science, including all publications available up to December 2025 that assessed liver function using dynSPECT imaging, standard laboratory function tests and clinical scoring systems. Search results were screened by two authors. Included studies were assessed for bias using the QUADAS-2 quality assessment test tool.
resultsSixteen eligible studies were incorporated in this review, involving 715 participants, of whom 87% (624) had hepatic diseases. Meta-analysis revealed correlations between dynSPECT measures of liver function and the laboratory tests, including Hepaplastin (r = 0.5471; 95% CI: 0.4523 to 0.6418), Indocyanine Green (ICG) (r = -0.461; 95% CI: -0.831 to -0.081), and Bilirubin (r = -0.425; 95% CI: -0.714 to -0.14). Furthermore, the comparison between the two dynSPECT parameters and clinical scoring systems, including the Child-Pugh score, MELD, and the histologic activity index (HAI), has a significant effect on liver disease assessment, with a combined p-value < 0.001.
conclusionDynSPECT is a useful tool for the assessment of liver function in patients with hepatic dysfunction, providing results comparable to clinical laboratory function tests and scoring systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.